INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55901, 306, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55902, 2506, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55903, 16253, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55904, 16254, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55905, 22238, 'Hydroxychloroquine', 'Seizures', '4-aminoquinolines may cause epileptic seizures in susceptible individuals.  Patients with epilepsy or an otherwise low seizure threshold may be at greater risk.  Therapy with 4-aminoquinolines, particularly chloroquine, should be administered cautiously in patients with epilepsy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55906, 306, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55907, 2506, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55908, 16253, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55909, 16254, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55910, 22238, 'Hydroxychloroquine', 'Glucosephosphate Dehydrogenase Deficiency', 'Hemolysis and acute renal failure have been reported during use of aminoquinolines in patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.  Therapy with aminoquinolines should be administered cautiously in these patients.  Blood cell counts and hemoglobin determinations should be performed regularly.  Aminoquinoline therapy should be discontinued immediately if signs suggestive of hemolytic anemia occur, such as marked darkening of the urine or sudden decrease in hemoglobin concentration or erythrocytic count.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55911, 306, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55912, 2506, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55913, 16253, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55914, 16254, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55915, 22238, 'Hydroxychloroquine', 'Liver Diseases', 'Aminoquinolines may concentrate in the liver.  Isolated cases of abnormal liver function and fulminant hepatic failure have been reported.  Therapy with aminoquinolines should be administered cautiously in patients with hepatic disease or alcoholism and in patients receiving other hepatotoxic drugs.  Periodic evaluation of hepatic function should be performed during prolonged therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55916, 306, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55917, 2506, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55918, 16253, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55919, 16254, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55920, 22238, 'Hydroxychloroquine', 'Myasthenia Gravis', 'Certain aminoquinolines such as chloroquine, and hydroxychloroquine should be used with caution in patients with myasthenia gravis (MG).  These agents may exacerbate or trigger new onset of symptoms in patients with previously diagnosed MG.  It is recommended to advise patients with MG about this possible side effect.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55921, 306, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55922, 2506, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55923, 16253, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55924, 16254, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55925, 22238, 'Hydroxychloroquine', 'Psoriasis', 'The use of aminoquinolines in patients with psoriasis may precipitate a severe attack of psoriasis. Aminoquinolines should not be used in these patients unless the potential benefits are anticipated to outweigh the risks.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55926, 306, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55927, 2506, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55928, 16253, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55929, 16254, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55930, 22238, 'Hydroxychloroquine', 'Diabetes Mellitus', 'Hydroxychloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic.  Care should be exercised when using hydroxychloroquine in diabetic patients.  Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine should have their blood glucose checked and treatment instituted as necessary.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55931, 306, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55932, 2506, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55933, 16253, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55934, 16254, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55935, 22238, 'Hydroxychloroquine', 'Heart Diseases', 'Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.  Therapy with hydroxychloroquine should be monitored in patients with heart conditions.  If cardiotoxicity is suspected, it is recommended to discontinue treatment with hydroxychloroquine to prevent life-threatening complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55936, 306, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55937, 2506, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55938, 16253, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55939, 16254, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55940, 22238, 'Hydroxychloroquine', 'Kidney Diseases', 'Hydroxychloroquine is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  A dosage adjustment is not required for patients with renal impairment.  Caution and monitoring should be exercised in patients with impaired renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55941, 1062, 'Hydroxyzine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55942, 14519, 'Hydroxyzine', 'Depressive Disorder', 'A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics.  Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations.  These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation.  Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55943, 1062, 'Hydroxyzine', 'Long QT Syndrome', 'Hydroxyzine is contraindicated in patients with a QT prolonged interval.  Cases of QT prolongation and Torsade de Pointes have been reported during postmarketing studies.  Most of the cases reported occurred in patients with other risk factors for QT prolongation, such as preexisting heart disease, electrolyte imbalances or arrhythmogenic drug use.  Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, family history of long QT syndrome or other predisposing conditions, as well as myocardial infarction, uncompensated heart failure, and bradyarrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55944, 14519, 'Hydroxyzine', 'Long QT Syndrome', 'Hydroxyzine is contraindicated in patients with a QT prolonged interval.  Cases of QT prolongation and Torsade de Pointes have been reported during postmarketing studies.  Most of the cases reported occurred in patients with other risk factors for QT prolongation, such as preexisting heart disease, electrolyte imbalances or arrhythmogenic drug use.  Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, family history of long QT syndrome or other predisposing conditions, as well as myocardial infarction, uncompensated heart failure, and bradyarrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55945, 1062, 'Hydroxyzine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55946, 14519, 'Hydroxyzine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55947, 1062, 'Hydroxyzine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55948, 14519, 'Hydroxyzine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55949, 1062, 'Hydroxyzine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55950, 14519, 'Hydroxyzine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55951, 1062, 'Hydroxyzine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55952, 14519, 'Hydroxyzine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55953, 1062, 'Hydroxyzine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55954, 14519, 'Hydroxyzine', 'Glaucoma', 'Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55955, 0, 'Ibritumomab tiuxetan', 'Pancytopenia', 'The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias.  Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve.  It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55956, 0, 'Ibritumomab tiuxetan', 'Hematologic Diseases', 'The radiation dose resulting from therapeutic exposure to Y-90 radiolabeled ibritumomab tiuxetan may result in secondary malignancies.  Myelodysplastic syndrome (MDS) and/or acute myelogenous leukemia (AML) has been reported in clinical trials with ibritumomab tiuxetan.  It is recommended to monitor patients for hematological toxicity including development of MDS or AML.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55957, 0, 'Ibandronate', 'Bisphosphonate-Associated Osteonecrosis of the Jaw', 'Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates.  Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures).  The manufacturers of bisphosphonates recommend discontinuation of bisphosphonate treatment for patients undergoing invasive dental procedures.  Patients who develop osteonecrosis of the jaw while on bisphosphonate therapy should receive care by an oral surgeon.  In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.  Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55958, 0, 'Ibandronate', 'Hypocalcemia', 'The use of bisphosphonates is contraindicated for the treatment of osteoporosis in patients with hypocalcemia.  These agents increase bone mineral density, a process that requires an adequate supply of calcium in the body.  Following the initiation of therapy, a short-term reduction in serum calcium and phosphate levels usually occurs due to inhibition of bone resorption, especially in patients with Paget''s disease, in whom the pretreatment rate of bone turnover may be greatly elevated.  Hypocalcemia and other disturbances of mineral metabolism, such as vitamin D deficiency, should be treated prior to initiation of therapy.  Appropriate intake of calcium and vitamin D should be ensured throughout the course of treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55959, 0, 'Ibandronate', 'Peptic Ulcer', 'Bisphosphonates may cause local irritation of the upper gastrointestinal mucosa.  Esophagitis and esophageal ulcers and erosions, occasionally with bleeding, as well as gastric and duodenal ulcers, have been reported, primarily with alendronate.  Because of their structural similarities, therapy with all bisphosphonates should be administered cautiously in patients with active upper gastrointestinal disorders.  The usual precautions should be followed closely to minimize the risk of irritation (i.e. taking the medication with a full glass of water after arising for the day and remaining upright for at least 30 minutes afterwards and until the first food intake of the day).  Therapy should be discontinued if dysphagia, odynophagia or retrosternal pain occurs.  The manufacturer of alendronate considers its use to be contraindicated in patients with abnormalities of the esophagus that may delay esophageal emptying, such as stricture or achalasia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55960, 0, 'Ibandronate', 'Kidney Diseases', 'Ibandronate is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min).  The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% to 60% of the absorbed dose).  Unabsorbed ibandronate is eliminated unchanged in the feces.  Renal clearance of ibandronate in patients with various degrees of renal impairment is linearly related to creatinine clearance (CrCl).  Treatment with intravenous bisphosphonates has been associated with renal toxicity manifested as deterioration in renal function and acute renal failure.  Obtain serum creatinine prior to each ibandronate sodium injection.  After ibandronate sodium injection, assess renal function, as clinically appropriate, in patients with concomitant diseases or taking medications that have the potential for adverse effects on the kidney.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55961, 0, 'Ibandronate', 'Asthma', 'There have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates.  Use of these agents in asthmatic and in aspirin-sensitive patients should be used with caution.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55962, 30261, 'Acalabrutinib', 'Arrhythmias, Cardiac', 'Atrial fibrillation and atrial flutter have been observed in patients treated with acalabrutinib.  It is recommended to monitor patients with abnormal heart rhythm for atrial fibrillation and atrial flutter and manage as clinically appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55963, 30261, 'Acalabrutinib', 'Hemorrhage', 'Serious hemorrhagic events, including fatal events, have occurred in patients treated with acalabrutinib.  Care should be exercised when using acalabrutinib in patients with bleeding disorders.  It is recommended to monitor for signs of bleeding and to consider the benefit-risk of withholding therapy for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55964, 30261, 'Acalabrutinib', 'Hepatic Insufficiency', 'Acalabrutinib is metabolized in the liver.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in subjects with mild or moderate hepatic impairment.  The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe hepatic impairment.  Close monitoring of liver function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55965, 30261, 'Acalabrutinib', 'Infections', 'Serious infections (bacterial, viral or fungal), including fatal events and opportunistic infections have occurred in patients treated with acalabrutinib.  Care should be exercised in patients at risk as in those at increased susceptibility to infection, such as neutropenic patients or those with a prior history of hepatitis B virus infection.  It is recommended to monitor patients for signs and symptoms of infection and treat as medically appropriate.  Consider prophylaxis in patients who are at increased risk for opportunistic infections.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55966, 30261, 'Acalabrutinib', 'Kidney Diseases', 'Acalabrutinib undergoes minimal renal elimination.  Based on the population pharmacokinetic analysis, no clinically relevant difference was observed in patients with mild or moderate renal impairment.  The pharmacokinetic of acalabrutinib has not been evaluated in patients with severe renal impairment or renal impairment requiring dialysis.  Close monitoring of renal function is recommended in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55967, 20724, 'Ibrutinib', 'Atrial Fibrillation', 'Atrial fibrillation and atrial flutter have occurred in patients treated with ibrutinib.  The risk is increased in patients with cardiac risk factors, hypertension, acute infections, and a previous history of atrial fibrillation.  It is recommended to monitor patients clinically for atrial fibrillation periodically and those patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness) or new onset dyspnea should have an ECG performed.  Atrial fibrillation should be managed appropriately, and if it persists to consider the risks and benefits of ibrutinib treatment and follow dose modification according to clinical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55968, 20725, 'Ibrutinib', 'Atrial Fibrillation', 'Atrial fibrillation and atrial flutter have occurred in patients treated with ibrutinib.  The risk is increased in patients with cardiac risk factors, hypertension, acute infections, and a previous history of atrial fibrillation.  It is recommended to monitor patients clinically for atrial fibrillation periodically and those patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness) or new onset dyspnea should have an ECG performed.  Atrial fibrillation should be managed appropriately, and if it persists to consider the risks and benefits of ibrutinib treatment and follow dose modification according to clinical guidelines.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55969, 20724, 'Ibrutinib', 'Hemorrhage', 'Cases of bleeding, including bruising, petechia, intracranial hemorrhage, including subdural hematoma; gastrointestinal bleeding, hematuria, post procedural hemorrhage, some leading to fatal bleeding events have been reported in patients treated with ibrutinib.  Patients receiving antiplatelet or anticoagulant therapy may be at an increased risk of hemorrhage and these patients should be closely monitored for signs of bleeding.  It is recommended to consider withholding ibrutinib for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55970, 20725, 'Ibrutinib', 'Hemorrhage', 'Cases of bleeding, including bruising, petechia, intracranial hemorrhage, including subdural hematoma; gastrointestinal bleeding, hematuria, post procedural hemorrhage, some leading to fatal bleeding events have been reported in patients treated with ibrutinib.  Patients receiving antiplatelet or anticoagulant therapy may be at an increased risk of hemorrhage and these patients should be closely monitored for signs of bleeding.  It is recommended to consider withholding ibrutinib for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55971, 20724, 'Ibrutinib', 'Pancytopenia', 'Cytopenias including neutropenia, thrombocytopenia, and anemia have been reported with use of ibrutinib.  Care should be taken with patients at risk, and it is recommended to monitor for complete blood counts monthly or as clinically appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55972, 20725, 'Ibrutinib', 'Pancytopenia', 'Cytopenias including neutropenia, thrombocytopenia, and anemia have been reported with use of ibrutinib.  Care should be taken with patients at risk, and it is recommended to monitor for complete blood counts monthly or as clinically appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55973, 20724, 'Ibrutinib', 'Hepatic Insufficiency', 'Ibrutinib is metabolized in the liver.  In clinical trials, patients with hepatic impairment showed an increase in ibrutinib exposure following a single dose administration.  It is recommended to monitor patients for signs of toxicity and follow dose modification as appropriate.  The use of ibrutinib is not recommended in patients with moderate or severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55974, 20725, 'Ibrutinib', 'Hepatic Insufficiency', 'Ibrutinib is metabolized in the liver.  In clinical trials, patients with hepatic impairment showed an increase in ibrutinib exposure following a single dose administration.  It is recommended to monitor patients for signs of toxicity and follow dose modification as appropriate.  The use of ibrutinib is not recommended in patients with moderate or severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55975, 20724, 'Ibrutinib', 'Hypertension', 'The use of ibrutinib may cause hypertension.  It is recommended to monitor for new onset hypertension or hypertension that is not adequately controlled after starting therapy and to adjust hypertensive medications and/or initiate antihypertensive treatment per clinical practices.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55976, 20725, 'Ibrutinib', 'Hypertension', 'The use of ibrutinib may cause hypertension.  It is recommended to monitor for new onset hypertension or hypertension that is not adequately controlled after starting therapy and to adjust hypertensive medications and/or initiate antihypertensive treatment per clinical practices.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55977, 20724, 'Ibrutinib', 'Infections', 'Fatal and non-fatal infections, including cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP), have been reported with the use of ibrutinib.  It is recommended to assess patients for fever and infections and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55978, 20725, 'Ibrutinib', 'Infections', 'Fatal and non-fatal infections, including cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP), have been reported with the use of ibrutinib.  It is recommended to assess patients for fever and infections and treat appropriately.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55979, 20724, 'Ibrutinib', 'Kidney Diseases', 'The use of ibrutinib in patients with mild to moderate renal impairment is not expected to influence on the exposure to ibrutinib.  Caution and close monitoring is recommended in patients with severe renal impairment or patients on dialysis as there are no data available for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55980, 20725, 'Ibrutinib', 'Kidney Diseases', 'The use of ibrutinib in patients with mild to moderate renal impairment is not expected to influence on the exposure to ibrutinib.  Caution and close monitoring is recommended in patients with severe renal impairment or patients on dialysis as there are no data available for these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55981, 20724, 'Ibrutinib', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome has been reported with ibrutinib therapy.  It is recommended to assess the baseline risk (e.g., high tumor burden) and take appropriate precautions.  Monitor patients closely and treat as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55982, 20725, 'Ibrutinib', 'Tumor Lysis Syndrome', 'Tumor lysis syndrome has been reported with ibrutinib therapy.  It is recommended to assess the baseline risk (e.g., high tumor burden) and take appropriate precautions.  Monitor patients closely and treat as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55983, 20724, 'Ibrutinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55984, 20725, 'Ibrutinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55985, 10785, 'Hyoscyamine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55986, 10785, 'Hyoscyamine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55987, 10785, 'Hyoscyamine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55988, 10785, 'Hyoscyamine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55989, 10785, 'Hyoscyamine', 'Lung Diseases', 'The use of systemic anticholinergics is contraindicated in the treatment of lower respiratory tract symptoms including asthma.  Muscarinic receptor antagonists reduce bronchial secretions, which can result in decreased fluidity and increased thickening of secretions.  However, ipratropium does not produce these effects and can be used safely in treating asthma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55990, 10785, 'Hyoscyamine', 'Myasthenia Gravis', 'Because antimuscarinic agents have anticholinergic effects, they are contraindicated in patients with myasthenia gravis.  Their use may be appropriate to reduce adverse muscarinic effects caused by an anticholinesterase agent.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55991, 10785, 'Hyoscyamine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55992, 10785, 'Hyoscyamine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55993, 10785, 'Hyoscyamine', 'Tachycardia', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with anticholinergics is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55994, 10785, 'Hyoscyamine', 'Coronary Artery Disease', 'Antimuscarinic agents block vagal inhibition of the SA nodal pacemaker.  These agents should be administered cautiously in patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization or ventricular tachycardia or fibrillation associated with antimuscarinic drugs is rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55995, 10785, 'Hyoscyamine', 'Stomach Ulcer', 'Antimuscarinic agents may cause a delay in gastric emptying and possibly antral stasis in patients with gastric ulcer.  Therapy with antimuscarinic agents should be administered cautiously to patients with gastric ulcer.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55996, 10785, 'Hyoscyamine', 'Gastroesophageal Reflux', 'Antimuscarinic agents decrease gastric motility and relax the lower esophageal sphincter which promotes gastric retention and can aggravate reflux.  These drugs should be administered cautiously in patients with gastroesophageal reflux or hiatal hernia associated with reflux esophagitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55997, 10785, 'Hyoscyamine', 'Colitis, Ulcerative', 'Antimuscarinic agents may suppress intestinal motility and produce paralytic ileus with resultant precipitation of toxic megacolon.  These drugs should be administered cautiously to patients with ulcerative colitis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55998, 10785, 'Hyoscyamine', 'Liver Diseases', 'Atropine-like agents undergo significant hepatic metabolism.  Therapy with atropine-like agents should be administered cautiously to patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (55999, 10785, 'Hyoscyamine', 'Renal Insufficiency', 'Atropine-like agents are primarily eliminated by the kidney.  Therapy with atropine-like agents should be administered cautiously to patients with renal disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (56000, 10785, 'Hyoscyamine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
